Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Randomised, Multicenter, Open-Label, Parallel-Group Study Comparing Adalimumab 40 Mg s.c. Eow Versus Infliximab 3 Mg/Kg i.v. Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 Mg/Kg Every 8 Weeks.

Project: Types of projects

  • Skjødt, Henrik (Project participant)
  • Østergaard, Mikkel (Project participant)
  • Andersen, Lis S, Graasten Gigthospital, Denmark (Project participant)
  • Tramsborg, Gorm, Glostrup Hospital, Denmark (Project participant)
  • Baslund, Bo, Rigshospitalet, Denmark (Project participant)
  • Hansen, Annette, Rigshospitalet, Denmark (Project participant)
  • Asmussen, Karsten, Bispebjerg Hospital, Denmark (Project participant)
  • Rintek, Ole, Gentofte Amtssygehus, Denmark (Project participant)
View graph of relations
Purpose: To establish whether RA patients with moderate to severe disease activity with unsustainable response to infliximab 3 mg/kg every 8 weeks have better efficacy with adalimumab 40 mg s.c. eow compared to infliximab 3 mg/kg i.v. every 6 weeks.
Research programme<ingen navn>

ID: 32565043